TG Therapeutics, Inc. (NASDAQ: TGTX) stock jumped 16 per cent on strong financial results, optimistic guidance and growing confidence in its flagship drug, Briumvi.
The company announced its financial results for the fourth quarter and the full year of 2024 before the market opened on Monday, and the numbers exceeded expectations.
TG reported a GAAP earnings per share (EPS) of USD$0.15 for Q4, paired with revenue of USD$108.19 million. These figures outperformed Wall Street estimates, signalling robust growth and operational success. For the full year, TG Therapeutics posted revenues of USD$310 million, reflecting a 250 per cent year-over-year increase.
Briumvi (ublituximab-xiiy), the company’s treatment for relapsing forms of multiple sclerosis (RMS), is the primary source of the company’s recent success. Launched in 2023, Briumvi has gained traction, with the company calling it the “fastest-growing MS drug” in its class. Sentiments on social media point out that Briumvi’s success positions TG Therapeutics as a rare biotech company generating significant profits.
Adding fuel to the fire, TG Therapeutics provided a positive outlook for the first quarter of 2025 during a Monday earnings call. Management expressed confidence in Briumvi’s continued momentum, citing accelerating new patient starts and an increasing share of repeat prescriptions.
The company’s guidance aligns with its broader 2025 business outlook. Analysts interpret this as a sign of confidence in capturing additional market share in the competitive MS treatment landscape.
Competitors like Roche (SWX: ROG) (OTCMKTS: RHHBY) and Novartis AG (NYSE: NVS) dominate this space, but Briumvi’s unique profile as an anti-CD20 monoclonal antibody, combined with its rapid adoption, is carving out a niche for TG Therapeutics.
Read more: Breath Diagnostics onboards new president and closes critical financing
Read more: Breath Diagnostics pioneers novel lung cancer breath test
TG Therapeutics rise is also about recognition
Beyond the financials, TG Therapeutics shared encouraging clinical updates that further buoyed investor sentiment.
The company brought up a 92 per cent success rate in five-year data from its Phase 3 ULTIMATE I & II trials for Briumvi in RMS patients. This long-term efficacy data reinforces the drug’s value proposition and differentiates it in a crowded market.
However, the stock’s rise today isn’t just about numbers—it’s also about recognition.
TG Therapeutics was recently added to Investor’s Business Daily’s prestigious Leaderboard, a curated list of top-performing stocks.
Additionally, the company’s ability to deliver consistent revenue beats—exceeding its own 2024 guidance by 24 per cent, according to some analyses—has shifted perceptions from skepticism to optimism.
The social media sentiment is clear. TG Therapeutics is no longer seen as a speculative biotech but as a company with strong fundamentals and a clear growth trajectory.
However, some risks still exist.
While the outlook is overwhelmingly positive, TG Therapeutics remains a biotech stock, a sector known for volatility. With only one marketed product, Briumvi, the company’s fortunes are heavily tied to its performance. External factors such as inflation, regulatory changes, or competition could pose challenges.
Stella Lynch
March 5, 2025 at 12:49 pm
I was living with MS for years before being officially diagnosed in 2021. I got annual MRIs, and I did not take any meds due to side effects. I had one flare up in 2021. My legs decided to a break, and I was numb from the waist down. I decided to try MS-4 from Uine Health Centre. The numbness and Muscle spasms went away after a couple of weeks, but it took almost 3 months to walk properly without a cane. In June, it will be four years without incident, and I am extremely happy that I made the decision to not take any meds and went for the MS-4 formula even though my neurologist got upset and one told me to quit my job because I will be disabled. Well, I am not disabled, I still refuse to take those meds, and I am doing just fine. Believe in yourself and go with your instincts. Doctors don’t know it all. I’m surprised a lot of people with MS haven’t heard of the MS-4 protocol, I got the treatment from uinehealthcentre I am absolutely confident that this protocol offers a viable solution. I hope you find it helpful.